Clinical Characterization of Antiphospholipid Syndrome by Detection of IgG Antibodies Against β2‐Glycoprotein I Domain 1 and Domain 4/5: Ratio of Anti–Domain 1 to Anti–Domain 4/5 As a Useful New Biomarker for Antiphospholipid Syndrome

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Arthritis & Rheumatology

• Publication date

  2015-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/art.39187PMID 25939498
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Autoantibody profiling of patients with antiphospholipid syndrome using an automated multiplexed immunoassay system.

  2014cited by this paper
• A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome.

  2014cited by this paper
• New Tests to Detect Antiphospholipid Antibodies: Anti-Domain I Beta-2-Glycoprotein-I Antibodies

  2014cited by this paper
• Utility of Antiphosphatidylserine/Prothrombin and IgA Antiphospholipid Assays in Systemic Lupus Erythematosus

  2013cited by this paper
• Clinical Evaluation Of Two Anti-Beta(2)glycoprotein I Domain 1 Autoantibody Assays To Aid In The Diagnosis and Risk Assessment Of The Antiphospholipid Syndrome

  2013cited by this paper
• Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome.

  2013cited by this paper
• What Have We Learned about Antiphospholipid Syndrome from Patients and Antiphospholipid Carrier Cohorts?

  2012cited by this paper
• Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome.

  2012cited by this paper
• Antiphospholipid antibody profiling: time for a new technical approach?

  2012cited by this paper
• β2‐Glycoprotein I: evolution, structure and function

  2011cited by this paper
• Antibodies to Domain I of β(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS).

  2011cited by this paper
• Pathogenesis of antiphospholipid syndrome: understanding the antibodies

  2011cited by this paper
• Anti-β2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile?

  2010cited by this paper
• Update of the guidelines for lupus anticoagulant detection

  2009cited by this paper
• The association between circulating antibodies against domain I of beta2‐glycoprotein I and thrombosis: an international multicenter study

  2009cited by this paper
• Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43.

  2007cited by this paper
• Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI.

  2006cited by this paper
• International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

  2006cited by this paper
• IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis.

  2005cited by this paper
• Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies.

  2004cited by this paper
• Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome.

  2003cited by this paper
• Prevalence and Clinical Correlations of Antibodies Against Six β2-Glycoprotein-I-Related Peptides in the Antiphospholipid Syndrome

  2003cited by this paper
• Anti-beta(2)-glycoprotein I antibodies in children with atopic dermatitis.

  2002cited by this paper
• Anti‐β2‐glycoprotein I antibodies in children with atopic dermatitis

  2002cited by this paper
• Distinguishing Features of Anti-β2 Glycoprotein I Antibodies between Patients with Leprosy and the Antiphospholipid Syndrome

  2002cited by this paper
• Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I.

  2001cited by this paper
• β2-glycoprotein I-dependent Anticardiolipin Antibodies Preferentially Bind the Amino Terminal Domain of β2-glycoprotein I

  2001cited by this paper
• Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria.

  1999cited by this paper
• 抗β2糖蛋白質I(β2GPI)自己抗体はβ2GPIの第一ドメイン上のエピトープを認識する

  1998cited by this paper
• Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI.

  1998cited by this paper
• Anti-β2 glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of β2GPI

  1998cited by this paper
• Anti- b 2 glycoprotein I ( b 2GPI) autoantibodies recognize an epitope on the first domain of b 2GPI

  1998cited by this paper
• Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

  1997cited by this paper
• Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome?

  1995cited by this paper

• Diagnosis of Antiphospholipid Syndrome by Chemiluminescent or Enzyme-Linked Immunosorbent Assay – A Comparison Study and Comprehensive Literature Review

  2025influential citation
• Novel advances on pathophysiological mechanisms, clinical manifestations, and treatment of antiphospholipid syndrome

  2025cites this paper
• Can we cure antiphospholipid syndrome?

  2025cites this paper
• The absence of standardization in antiphospholipid antibody testing may favor the use of 99th percentile cutoffs in antiphospholipid syndrome classification

  2025cites this paper
• Mechanisms sensitive to different drugs mediate a pro-adhesive and pro-thrombotic platelet phenotype in anti-phospholipid syndrome

  2025cites this paper
• Anti-β2 glycoprotein domain 1 antibody as a diagnostic marker for antiphospholipid syndrome and a predictor of thrombosis: a systematic review and meta-analysis

  2025cites this paper
• Lupus Anticoagulant and Anti-Prothrombin Antibodies: Embracing the Future.

  2025cites this paper
• Antiphospholipid IgG Certified Reference Material ERM®-DA477/IFCC: a tool for aPL harmonization?

  2025cites this paper
• Changes in serum immunoglobulin G glycosylation patterns for antiphospholipid syndrome patients with lectin microarray

  2024cites this paper
• Antiphospholipid antibody testing.

  2024cites this paper
• Antiphospholipid syndrome in children.

  2024cites this paper
• Rethinking antiphospholipid syndrome to guide future management and research

  2024cites this paper
• Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones?

  2024cites this paper
• Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management

  2023cites this paper
• 16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome laboratory diagnostics and trends

  2023cites this paper
• The Potential Role of Neutrophils in Enhancement of Thrombotic Risk in Patients with Primary Antiphospholipid Syndrome

  2023cites this paper
• Pursuing appropriateness in antiphospholipid antibodies testing: Feasibility study with a reflex test approach for anti-β2GPI I domain.

  2023cites this paper
• Anti-β2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China

  2023cites this paper
• Laboratory Testing for Non-criteria Antiphospholipid Antibodies: Antibodies Toward the Domain I of Beta2-Glycoprotein I (aDI).

  2023cites this paper
• Extra-criteria antiphospholipid antibodies in patients with small vessel brain lesions and clinical manifestations associated with antiphospholipid syndrome.

  2023cites this paper
• Evolution of Antiphospholipid Syndrome

  2023cites this paper
• Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection

  2022cites this paper
• Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome

  2022cites this paper
• COVID-19 and antiphospholipid antibodies

  2022cites this paper
• Solid Phase Assays for Antiphospholipid Antibodies.

  2022cites this paper
• Antiphospholipid syndrome: the need for new international classification criteria

  2021cites this paper
• β2 glycoprotein I participates in phagocytosis of apoptotic neurons and in vascular injury in experimental brain stroke

  2021cites this paper
• Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome

  2021cites this paper
• Effects of anti‐beta 2‐glycoprotein 1 antibodies and its association with pregnancy‐related morbidity in antiphospholipid syndrome

  2021cites this paper
• Antibodies and diagnostic tests in antiphosholipid syndrome

  2021cites this paper
• COVID-19 and antiphospholipid antibodies

  2021cites this paper
• Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One

  2021cites this paper
• Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review

  2021cites this paper
• Are antiphospholipid antibodies just a common epiphenomenon or are they causative of immune-mediated coagulopathy in COVID-19?

  2021cites this paper
• B cells in primary antiphospholipid syndrome: Review and remaining challenges.

  2021cites this paper
• Does incomplete obstetric antiphospholipid syndrome really exist?

  2021cites this paper
• Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis

  2020cites this paper
• Antiphospholipid Syndrome.

  2020cites this paper
• The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS

  2020cites this paper
• “Non-criteria” antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort

  2020cites this paper
• [Seronegative antiphospholipid syndrome: Myth or reality?]

  2020cites this paper
• Anti-domain 1 β2 glycoprotein antibodies increase expression of tissue factor on monocytes and activate NK Cells and CD8+ cells in vitro

  2020cites this paper
• Anti‐phospholipid antibodies and reproductive failures

  2020cites this paper
• Covid-19 and autoimmunity

  2020cites this paper
• Prevalence, specificity, and clinical association of anti-phospholipid antibodies in COVID-19 patients: are the antibodies really guilty?

  2020cites this paper
• Anti-Domain I β2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study.

  2020cites this paper
• “APS pregnancy – The offspring”

  2020influential citation
• 16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome

  2020cites this paper
• Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome

  2020cites this paper
• The Weight of IgA Anti-β2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome

  2020cites this paper
• Non-criteria Antiphospholipid Antibodies: a narrative review.

  2020cites this paper
• Detection of anti‐domain I antibodies by chemiluminescence enables the identification of high‐risk antiphospholipid syndrome patients: A multicenter multiplatform study

  2019cites this paper
• P2X7 receptor restrains pathogenic Tfh cell generation in systemic lupus erythematosus

  2019cites this paper
• The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases.

  2019cites this paper
• Are Anti-Phospholipid Syndrome and Systemic Lupus Erythematosus Two Different Diseases? A 10-Year Late Remake.

  2019cites this paper
• Update on the Diagnosis and Anticoagulant Treatment of the Antiphospholipid Syndrome

  2019cites this paper
• Challenges and Advances in SLE Autoantibody Detection and Interpretation

  2019cites this paper
• Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome

  2019cites this paper
• Autoimmunity Reviews

  2019cites this paper
• Antiphospholipid Syndrome

  2019cites this paper
• Anti-β2GPI domain 1 antibodies stratify high risk of thrombosis and late pregnancy morbidity in a large cohort of Chinese patients with antiphospholipid syndrome.

  2019cites this paper
• Mechanisms of Antiphospholipid Syndrome Induction: Role of NKT Cells

  2019cites this paper
• Treatment of antiphospholipid syndrome beyond anticoagulation.

  2019cites this paper
• Beyond thrombosis: Anti-β2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome.

  2018cites this paper
• Therapy for antiphospholipid miscarriages: Throwing the baby out with the bathwater?

  2018cites this paper
• Update on Antiphospholipid Syndrome: Ten Topics in 2017

  2018cites this paper
• Antiphospholipid syndrome during pregnancy

  2018cites this paper
• New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats

  2018cites this paper
• University of Birmingham Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis

  2018cites this paper
• PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome

  2018cites this paper
• The clinical value of assays detecting antibodies against domain I of β2-glycoprotein I in the antiphospholipid syndrome.

  2018cites this paper
• Management of antiphospholipid syndrome

  2018cites this paper
• Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective.

  2018cites this paper
• Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?

  2018cites this paper
• Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases

  2018cites this paper
• Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases

  2018cites this paper
• Laboratory Markers With Clinical Significance in the Antiphospholipid Syndrome

  2017cites this paper
• Mechanisms of Action of the Antiphospholipid Antibodies

  2017cites this paper
• Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?

  2017cites this paper
• Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests

  2017cites this paper
• Prevalence and Thrombotic Risk Assessment of Anti-β2 Glycoprotein I Domain I Antibodies: A Systematic Review

  2017cites this paper
• Detection of Anti-Domain I β-2 Glycoprotein I Antibodies as New Potential Target in Antiphospholipid Syndrome Diagnosis

  2017influential citation
• The Clinical Relevance of Noncriteria Antiphospholipid Antibodies

  2017cites this paper
• Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances

  2017cites this paper
• Coexistence of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies suggests strong thrombotic risk

  2017cites this paper
• Laboratory Diagnostics of Antiphospholipid Syndrome

  2017cites this paper
• The Significance of Antibodies against Domain I of Beta-2 Glycoprotein I in Antiphospholipid Syndrome

  2017cites this paper
• Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein are Strongly Associated with the Occurrence of Acute Thrombotic Events

  2016cites this paper
• Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome

  2016cites this paper
• Antiphospholipid syndrome.

  2016cites this paper
• Das Antiphospholipid-Syndrom im Kindes- und Jugendalter

  2016cites this paper
• Recognition and management of antiphospholipid syndrome

  2016cites this paper
• Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome

  2016cites this paper
• Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers

  2016cites this paper
• Evaluation of three fully automated immunoassay systems for detection of IgA anti‐beta 2‐glycoprotein I antibodies

  2016cites this paper
• The role of anti-phospholipid antibodies in autoimmune reproductive failure.

  2016cites this paper
• Chapter 3. Mechanisms of Action of the Antiphospholipid Antibodies

  2016cites this paper
• APS - Diagnostics and challenges for the future.

  2016cites this paper
• Prevention & treatment of obstetrical complications in APS: Is hydroxychloroquine the Holy Grail we are looking for?

  2016cites this paper
• Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools

  2016cites this paper